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ABSTRACT: Cranberry (Vaccinium macrocarpon) juice is
traditionally used for the prevention of urinary tract infections.
Human urine produced after cranberry juice consumption can
prevent Escherichia coli adhesion, but the antiadhesive urinary
metabolites responsible have not been conclusively identified.
Adult female sows were therefore fed spray-dried cranberry
powder (5 g/kg/day), and urine was collected via catheter.
Urine fractions were tested for antiadhesion activity using a
human red blood cell (A+) anti-hemagglutination assay with
uropathogenic P-fimbriated E. coli. Components were isolated
from fractions of interest using Sephadex LH-20 gel filtration
chromatography followed by HPLC on normal and reversed-
phase sorbents with evaporative light scattering detection. Active urine fractions were found to contain a complex series of
oligosaccharides but not proanthocyanidins, and a single representative arabinoxyloglucan octasaccharide was isolated in
sufficient quantity and purity for full structural characterization by chemical derivatization and NMR spectroscopic methods.
Analogous cranberry material contained a similar complex series of arabinoxyloglucan oligosaccharides that exhibited
antiadhesion properties in preliminary testing. These results indicate that oligosaccharides structurally related to those found in
cranberry may contribute to the antiadhesion properties of urine after cranberry consumption.
Cranberry [Vaccinium macrocarpon Ait., (Ericaceae)]products are popular and widely available in U.S. food,
juice, and dietary supplement markets.1 Cranberry juice is
commonly used as a folk remedy for the prevention of urinary
tract infections (UTIs). P-Fimbriated Escherichia coli have been
found to cause at least 80% of uncomplicated, community-
acquired UTIs,2,3 and recurrent UTIs are an increasingly
recognized problem.4 The overall high incidence of UTIs
results in estimates of billions of dollars spent annually ($2.3
billion in 2010) for direct health care and other societal
costs.4,5 The prevention of UTIs is preferable to treatment
with antimicrobial agents, as the use of preventive strategies
would not provide a selective pressure for the development of
antibacterial drug resistance.6,7 Preventative therapies are also
generally equally effective against both drug-susceptible and
drug-resistant strains of bacteria.6 As the initiation of a UTI
requires the initial step of bacterial adhesion to uroepithelial
membranes, compounds or products that interfere with
bacterial adhesion are of great medical interest.6 Anecdotal
and clinical evidence supports the ability of cranberry products
to help prevent UTIs by inhibiting bacterial adhesion in the
urinary tract after consumption of cranberry.8−11 Some clinical
reports, however, are inconclusive or do not directly support
the use of cranberry for preventing UTIs.12,13 This controversy
prompts questions regarding which types of UTIs can be
prevented by cranberry and highlights the essential need for a
better understanding of cranberry antiadhesive constitu-
ents.14−17
Cranberry juice and various extracts and other preparations
of cranberry have shown the ability to prevent the adhesion of
P-fimbriated E. coli to surfaces in several studies and in vitro
biological assays.18−22 Cranberry proanthocyanidins (PACs),
specifically PAC dimers, trimers, and oligomers that contain at
least one A-type linkage (Figure 1), have been isolated from
cranberry and shown in vitro to prevent the adhesion of P-
fimbriated E. coli to surfaces.23−25 The predominant hypothesis
Special Issue: Special Issue in Honor of Drs. Rachel Mata and
Barbara Timmermann
Received: December 9, 2018
Published: March 15, 2019
Article
pubs.acs.org/jnpCite This: J. Nat. Prod. 2019, 82, 589−605
© 2019 American Chemical Society and
American Society of Pharmacognosy 589 DOI: 10.1021/acs.jnatprod.8b01043
J. Nat. Prod. 2019, 82, 589−605
This is an open access article published under an ACS AuthorChoice License, which permits




















































































regarding cranberry antiadhesion properties since 1998 has
therefore been that PACs are the primary compounds
responsible for the antiadhesion properties of cranberry and
for the ability of cranberry materials to prevent UTIs.
In spite of the recognized antiadhesion properties of PACs,
questions exist regarding the role of these compounds in the
antiadhesion properties of urine after cranberry consumption.
PACs are known to form nonspecific, covalent bonds with
proteins26 and recent studies have indicated that PACs have a
low absorption and bioavailability, with limited transport
across Caco-2 intestinal epithelial cell monolayers.27 A PAC-
type drug (crofelemer) has been approved by the U.S. FDA for
the treatment of noninfectious diarrhea in HIV patients,28 and
it has been proposed that PACs could have protective effects
for intestinal epithelial cells by preventing extraintestinal E. coli
invasion.29 Studies that have been specifically designed to
detect the presence of low levels of PACs in human urine and
blood plasma have failed to identify these compounds at
biologically relevant concentrations, although some known
PAC metabolites have been identified.30−32 These data support
the hypotheses that PACs are primarily eliminated by the fecal
route in humans, that intact PACs are not present in urine at
biologically relevant concentrations after cranberry consump-
tion, and that PACs are therefore unlikely to be directly or
solely responsible for the antiadhesion properties of urine
produced after cranberry consumption.
Human volunteers who consume cranberry juice produce
urine that has antiadhesive properties.10,11,31−35 Antiadhesion
activity appears shortly after consumption of the juice until
about 8 h later, and maximum antiadhesion effects are
observed within 4 to 6 h of ingestion.31,34,35 This suggests
rapid absorption and excretion of antiadhesive compounds into
urine.36 Atomic force microscopy (AFM) adhesion mechanism
studies have shown that cranberry compounds are able to
directly interfere with specific ligand−receptor binding
interactions between bacteria and epithelial cells,18 that
compounds in addition to PACs are present in cranberry
that can affect bacterial adhesion,37,38 and that antiadhesive
components reach the urine after cranberry consumption.35
Studies on cranberry fractions containing nondialyzable
material (NDM) also show antiadhesive activity for fractions
that do not contain PACs.39 Together, these data further
support the hypothesis that additional, non-PAC compounds
may be responsible for or may contribute to the antiadhesion
properties of urine after the consumption of cranberry
products.
Identification of the antiadhesive urinary compounds that
are present as a result of cranberry consumption is essential for
future studies regarding the bioactive constituents of cranberry
products and the clinical efficacy of cranberry products for the
prevention of UTIs. The initial objective of this study was
therefore the isolation and identification of antiadhesive
urinary compounds produced as a result of cranberry
consumption. When the compounds isolated were found to
be unrelated to PACs, we also pursued the secondary objective
of determining if cranberry compounds could be a possible
source of the urinary compounds identified.
The newest hypothesis regarding cranberry antiadhesion
compounds is that complex carbohydrates, specifically
arabinoxyloglucans related to those found in cranberry, may
be at least partly responsible for the post-cranberry
consumption antiadhesion properties of urine. This hypothesis
was first presented publicly by us in July 2010 at the joint
meeting of the American Society of Pharmacognosy and the
Phytochemical Society of North America in St. Petersburg,
Florida, USA, and is reported in the abstract for that meeting.40
Since the date of this initial presentation, and later disclosures
in 2011−201341 and in 2014,42 additional researchers have
pursued investigations of cranberry oligosaccharides and their
biological properties.43−46 Recent publications on this subject
have provided additional support for some of our initial
findings presented here, including the presence of arabinox-
yloglucans in cranberry materials43,44 and the possible
antiadhesion properties of these compounds.39,44,45 Additional
work has focused on the complete structural elucidation of
oligosaccharides from cranberry.47,48 To date, no other studies
have yet to connect cranberry oligosaccharides to post-
cranberry-treatment urinary antiadhesion compounds. This
report describes the isolation and full structural character-
ization of an arabinoxyloglucan oligosaccharide from a porcine
urine fraction with antiadhesion properties and presents
evidence that supports the hypothesis that cranberry
oligosaccharides are the source of this compound.
Figure 1. Structure for an example of an oligomeric PAC with
indicated A- and B-type linkages.
Table 1. Details of the Swine Urine Collections Used as Source Material
sample code urine collection dates received by UM animal number urine volumea (L) solute concentrationa (g/L)
FC 2006/10/27 (control, 1 day) 2006/12 5081 2.0 18
F 2006/10/31−2006/11/02 (3 days treatment) 2006/12 5081 7.0 20
H 2008/06/24−2008/06/27 (4 days treatment) 2008/07 5023 3.5 17
I 2008/06/24−2008/06/27 (4 days treatment) 2008/07 8401 2.5 18
aApproximate values.
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■ RESULTS AND DISCUSSION
This study was initiated in 2004 and isolation efforts began in
2006. At the time, little was known regarding the bioavailability
of PACs, and PACs were the primary recognized antiadhesive
compounds associated with cranberry. Initial isolation efforts
therefore focused on attempts to isolate PACs from treatment
urine materials.42 As work progressed, evidence accumulated
that PACs were not the target compounds in the bioactive
fractions, and isolation efforts continued with the target of an
unknown, at that time, compound. Ultimately, complex
carbohydrates, specifically oligosaccharides, were identified as
the probable target compounds responsible for the anti-
adhesion activity of urine fractions.
Composition of Active Urine Fractions. Character-
ization. The source material for this study was obtained over
several years from multiple collections of swine urine after
cranberry feeding (Table 1). Independent of the urine
collection set, bioactive urinary components were consistently
present in aqueous urine fractions after extraction with organic
solvents, and urinary profiles of putative active constituents
were consistent across samples. Antiadhesion activity (Table
2) was detected in some EtOAc fractions (HCE, ICE) but not
others (FB, HCM, ICM, HD, ID), and insufficient amounts of
these materials prevented further investigation. The control
urine EtOAc fraction (FCE) also displayed possible bioactivity,
indicating that constitutive urinary metabolites or dietary
sources other than cranberry may be responsible for the
activity observed in some EtOAc fractions. Efforts were
therefore focused on the isolation of possible bioactive
components from aqueous fractions.
Relative bioactivity results for selected samples are shown in
Table 2 and Table S1 (Supporting Information). Assay results
are qualitative (Section S1, Supporting Information), but
provided sufficient information to guide isolation efforts.
Through the submission of multiple samples and sample
replicates, it was found that a minimum starting amount of 10
mg of material was required to avoid possible false negative
results for fractions with unknown constituents.42 At the time
of this study, alternative antiadherence assays were unavail-
able.21,22 Sample limitations therefore dictated that priority be
given to the isolation and characterization of putative bioactive
components in preference to comprehensive bioassay testing of
urine fractions at each step of the isolation protocol.
The majority of the material from the F urine collection was
consumed by method development and bioassay testing. The
active FF material yielded active Sephadex LH-20 fractions
Table 2. Anti-Hemagglutination Assay Results for Urine and Cranberry Samples
sample type sample relative activity
raw material F + FC − − H +/− I +/− CJ + +
solids FG − − HG − −
EtOAc FB − FCE +/− HCEa + ICEa + +
HCMb − − ICMb − −
EtOAc/MeOH HD − − ID − −
aqueous FF + FC1 − HF + IF +/− CJA + +
Sephadex LH-20 fractions FA +/− FC1-1 − − HF1-1 + + HI1c + + CJA1-02 + +
FA1 + + FC1-2 − − HF1-2 +/− HI2d + CJA2-02f + +
FA2 + FC1-3 − − HF1-3 − HI3e − − CJA2-03f +/−
FA3 − − HF1-4 − CJA2-04f +/−
FA4 +/− HF1-5 − − CJA2-05f −
FA5 − − HF1-6 −
HF1-7 − −
aWater-soluble portion of EtOAc fraction. bWater-insoluble portion of EtOAc fraction soluble in MeOH or EtOAc. cHI1 = HF2-1 + IF1-1. dHI2 =
HF1-1 + HF2-2 + IF1-2. eHI3 = HF1-2 + IF1-3 + HF2-3. fFractions of the CJA2 Sephadex LH-20 column are described in the accompanying
article.47
Figure 2. Analytical HPLC-ELSD and UV (PDA Max Plot) chromatograms for active fraction HF1-1. Comparison of the ELS and UV
chromatograms for the active urine fraction HF1-1 (0.52 mg in 20 μL injection; 26 mg/mL) indicates that a set of major fraction components
(box) is not visible by UV detection methods. Similar UV-transparent components were present in the active FA1 fraction. The semiquantitative
nature of ELSD makes it possible to determine that the UV−visible component of HF1-1 is of relatively low concentration. Line overlay is %
composition of water; counter solvent is MeOH.
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that consistently eluted as the first 1−3 fractions (Tables S1
and S2, Supporting Information), permitting enrichment for
the active 1−2% of total F urine materials into fraction FA
(Section S2, Supporting Information). This material was
further fractionated by Sephadex LH-20 (Table S3, Supporting
Information) to give the active fractions FA1 (0.030 g) and
FA2 (0.887 g).42 Active components were found to be
relatively stable under different storage and handling
conditions for more than four years (data not shown).42
Analytical HPLC analyses of the enriched FF fractions FA1
and FA2 using multiple stationary phases and solvent systems
eventually led to the observation of multiple UV-transparent
components using evaporative light scattering detection
(ELSD) (Section S3, Supporting Information). LC-micro-
TOFMS analyses of fractions FA1 and FA2 were inconclusive
(data not shown, Section 2b, Supporting Information),
possibly due to a lack of method optimization, as the target
compounds at the time of analysis were completely unknown.
While ELSD is a destructive detection method and resulted in
mass losses during split detection−collection preparative
separations, it allowed for the detection of nonvolatile and
semivolatile compounds regardless of the presence of specific
structural features such as chromophores. ELSD was therefore
the ideal detection method for this project, especially during
the initial method development phase when insufficient
information was available about the chemical nature of the
target compounds to allow for the selection of a more
customized or compound-specific approach.42
Further HPLC method optimization was pursued using
comparisons of FA1, FA2, HF1-1, HF1-2, and other active
samples. A complex profile of UV-transparent components
(e.g., HF1-1; Figure 2) was consistently present in antiadhesive
fractions of urine collected from three different swine after
cranberry consumption, but not in control fractions (Sections
S2 and S3, Supporting Information).
Comparisons between 1H NMR spectra of active fractions
FA1, FA2, HF1-1, HI1, and HI2 (Figure 3) indicated the
presence of similar components. Comparisons of these spectra
with those of synthesized trimeric and tetrameric PACs
(Figure S1, Supporting Information), however, indicated that
the 1H NMR spectra of active urine fractions did not contain
the characteristic overlapping aromatic resonances of the A-
and B-rings of PAC constituent units. Although 1H NMR
spectra of crude active urine fractions did contain resonances
in the aromatic region, these resonances were absent from
enriched fractions with higher activity, were present in
analogous inactive control fraction FC1-1, and were therefore
likely due to simple aromatic acids commonly found in
mammalian urine (Figures S2 and S3, Supporting Informa-
tion).49,50 The use of TLC spray reagents that produced color
reactions characteristic of flavonoids (e.g., vanillin, p-
anisaldehyde) further indicated that PACs and other flavonoids
were not present in the active FA1 and FA2 fractions (data not
shown; Section S2b, Supporting Information).
1H NMR and TLC-based comparisons of active urine
fractions FA1 and FA2 with various carbohydrate standards
indicated that the components of these fractions were
carbohydrates even though the possible presence of mono-
saccharides within these fractions had been eliminated through
chromatography (Section S2c, Supporting Information). The
dominant 1H NMR resonances in D2O were indicative of
carbohydrates (Figure 3 and Figure S29, Supporting
Information)51 and reminiscent of those of apple pectin
(Figure S19, Supporting Information), but the active urine
fractions had significantly different characteristics in aqueous
solution than pectin. Comparisons with standard samples of D-
glucose, sucrose, fructose, corn starch, and sodium citrate by
TLC, using various carbohydrate-specific spray reagents (e.g.,
ninhydrin, p-anisidine, bromocresol green), further supported
the absence of mono- or disaccharides (data not shown). It
was therefore concluded that the components of interest in
enriched urine samples were complex oligosaccharides.
Separations. The H and I urine collections provided
sufficient material to permit further characterization and
separation of the active fraction components. These materials
were separately extracted and fractionated following the
protocols developed with FF and earlier urine samples (Figure
4; Tables S2−S4, Supporting Information). As with the FF
fractions, the active constituents remained in the aqueous layer
after EtOAc extraction and eluted early from Sephadex LH-20
columns, with fractions HF1-1, HF2-1+IF1-1 (as HI1), and
HF2-2+IF1-2 (as HI2) giving the best bioactivity results for
the enriched samples tested (Table 2). All subsequent fractions
were not tested in order to preserve material for isolation
Figure 3. 1H NMR spectra of Sephadex LH-20 urine fractions of
interest, 400 MHz, D2O. FA, HF, and IF materials are the aqueous
fractions from three different source animals (see Tables 2 and 3 and
Figures 4 and 6). Spectra were acquired on ∼10 mg of each material
at similar concentrations. See Section S3 (Supporting Information)
for additional details on the composition and bioassay testing of HI
Atlantis dC18 subfractions. Fractions FA2 and HI3 had the lowest
antiadhesion activity of the fractions shown in this figure.
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efforts, and comparisons of the analytical HPLC-UV/ELSD
profiles of active and inactive fractions were used to guide
further method development and isolation (Figure 5; Figure S4
and Section S3, Supporting Information). The HPLC-ELSD
comparative analyses indicated that a series of UV-transparent
components eluting between 16 and 25 min (Figure 5) with an
optimized reversed-phase HPLC method were consistently
present in active samples across multiple feedings and
separations and absent from control samples.
Materials from the H and I treatment urines were handled
separately through step 3 of the general isolation protocol
(Figure 4). Sephadex LH-20 fractions from the two source
materials were combined for preparative reversed-phase
separations (step 4, Figure 4) and for subsequent semi-
preparative normal-phase separations (step 5, Figure 4) based
on similarities of their oligosaccharide elution profiles as
observed by analytical HPLC-ELSD (Sections S3, Supporting
Information). These combinations provided increased
amounts of material for subsequent separations, but difficulties
with resolution between the various individual oligosaccharides
in the series made it difficult to meaningfully recombine the
final fractions obtained (Table S12 and Section S3, Supporting
Information). An overview of the fractions generated during
the HPLC purification steps, showing their relationships to
each other and to the various parent fraction materials, is
presented in Figure 6.
Two major fractions of the UV-transparent series of
compounds detectable in HF2-2 (Figure 7, Table S9,
Supporting Information), HF2-2P1t20 (11.9 mg) and HF2-
2P1t22 (17.1 mg), contained closely related complex
oligosaccharides as determined by chromatography and
NMR data analyses. Further separation of the HF2-2P1t20
fraction after combination with the closely related fraction IF1-
3P1t20 yielded the primary component of this fraction as HF2-
2P1t20A17 (8.8 mg) (Table S19, Figures S40 and S41, and
Section S3, Supporting Information). A sufficient amount of
this material was available to allow for the full structural
characterization of compound 1 by MS and classical
carbohydrate structural analyses (Section S4, Supporting
Information) and to obtain supporting data for structural
assignments via NMR spectroscopy (Figures 8−11; Figures
S5−S13, Supporting Information). An insufficient amount was
available, however, for reliable bioassay testing. The HF2-
2P1t22 fraction yielded a series of at least six closely related
oligosaccharides as visible by HPLC-ELSD (Figure 12; Figures
S39 and S41, Supporting Information). Three of these
compounds, HF2-2P1t22A17 (1.9 mg), HF2-2P1t22A18 (1.8
mg), and HF2-2P1t22A19 (1.9 mg), could be isolated in
sufficient amounts for analysis by 1H NMR spectroscopy in
D2O (Figure 13; Figure S42, Supporting Information), but
insufficient amounts were available for further purification
efforts or bioassay testing. Full structural assignments could
not be made from the data obtained, but characteristic
resonances could be detected at δH 4.4, 4.6, 5.0, 5.1, and 5.2 in
the 1H NMR spectra. These resonances were later determined
to correspond to the anomeric protons for arabinoxyloglucan-
type oligosaccharides similar to 1 and purified cranberry
oligosaccharides.47,48 Comparisons of 1D and 2D NMR data
obtained (in DMSO-d6) for the parent fractions HF2-2P1t20
and HF2-2P1t22 indicated that the mixed compounds present
in fraction HF2-2P1t22 were all structurally related to the
primary component of HF2-2P1t20, compound 1 (Figure 14;
Figures S32 and S33, Supporting Information), and that this
series of compounds likely contains structures with 7−9
monosaccharide units (DP 7−9) with variations in linkage
positions and monomer composition.
The Oligosaccharide Series. The oligosaccharide series
present in swine urine samples is highly complex, with as many
as 50+ possible distinct compounds, and this series could not
Figure 4. General purification protocol used for the isolation of urine
and cranberry oligosaccharides.
Figure 5. Analytical HPLC-ELSD chromatograms for Sephadex LH-
20 fractions HF1-1, HF1-2, and HF1-3 (Atlantis dC18). UV
transparent components of interest (box), identified in the active
fraction HF1-1 between 16 and 25 min, are detectable at low
concentrations in the moderately active fraction HF1-2 and are absent
from the inactive fraction HF1-3. All three samples were injected at
the same concentration (50 μL injection, 10 mg/mL). The boxed
components visible in the HF1-1 chromatogram are undetectable by
UV (Figure 2; Figure S4, Supporting Information). Line overlay is %
composition of water; counter solvent is MeOH.
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be fully resolved or characterized with the resources available
for this study. Multiple minor compounds were observed in
HPLC-ELSD chromatograms, but collection attempts via
preparative and semipreparative separations yield less than 2
mg each for most of these fractions (Table S12 and Section S3,
Supporting Information). Subsequent injections on alternate
stationary phases with different chromatographic properties
(e.g., Atlantis dC18 fraction injected onto a Polyamine column)
often yielded multiple compounds from what had previously
appeared to be a single eluting component. This chromato-
graphic characteristic indicated the presence of compounds
with closely related structures and properties, but confounded
isolation efforts. Further discussion of this observation as
applied to the isolation attempts concerning fraction IF1-3 and
its subfractions is provided in the Supporting Information
(Section S3c, Figures S43−S46). While the oligosaccharide
nature of many of these fractions could be established by 1H
NMR spectroscopy in both DMSO-d6 and D2O, the data
quality was insufficient to reliably distinguish or meaningfully
compare any two subfractions with different retention times
and different parent materials (data not shown), thereby
Figure 6. Overview of the various samples and fractions of interest showing their origin materials, relationships, and similarities of composition. All
materials and fractions shown contain ELS-detectable oligosaccharides. Rounded boxes, rows, and columns indicate materials with similar
methodological origins (e.g., sets of column fractions) or chemical characteristics as determined by HPLC-ELSD and 1H NMR spectroscopy. For
example, CJP1t23 is an Atlantis dC18 column fraction derived from CJ material that is similar in composition to HF2-2P1t20 and IF1-3P1t20. The
fraction HF2-2P1t20 was derived from the parent materials HF2-2 + IF1-2 when they were separated on the Atlantis dC18 sorbent. HF2-2P1t20
was combined with IF1-3P1t20 and separated on the Polyamine II sorbent to yield HF2-2P1t20A17, a fraction that was determined to be pure
enough to yield full structural elucidation of compound 1.
Figure 7. Portion of the preparative HPLC-ELSD chromatogram for
HF2-2, R5 (Atlantis dC18). Resolution of this separation is
representative of the series of six preparative-scale separations for
this sample. Fractions were combined across all six separations (runs
1−6) (Table S9 and Figure S30, Supporting Information). Line
overlay is % composition of water; counter solvent is MeOH.
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preventing rational fraction recombinations and further
separation efforts. These observations and more recent MS-
based studies on cranberry arabinoxyloglucans43 support the
hypothesis that the series of compounds detected in urine
during this study is a complex series of oligosaccharides based
on a core structural theme with similar monosaccharide
composition and variations in connectivity and monomer unit
ratios.
Complete structural elucidation of all oligosaccharides
present in the urine was beyond the scope of this project
due to the limited quantities of material isolated, the
complexity of the probable compound structures, and a
limited availability of general resources for continuing the
investigation. Preliminary, approximate, mass recovery calcu-
lations indicated that oligosaccharide urinary metabolites are
likely to be within a reasonable range for bioactivity,49 with
single components present at a minimum concentration of
∼1−5 μg/mL urine.
Structure Elucidation. Carbohydrate Structural Anal-
yses. The structure of 1 was established using standard
carbohydrate derivatization and analysis procedures (Section
S4, Supporting Information), MSn fragmentation data (Section
S5, Supporting Information), and 1D and 2D NMR experi-
ments (Figures 8−11; Figures S5−S13, Supporting Informa-
tion). Glycosyl composition analysis by GC-MS of the TMS
methyl glycosides of 1 indicated it was composed of arabinose,
xylose, and glucose with a molar ratio of 1:1:2 (Table S5,
Supporting Information). The mass fragments of the TMS
methyl glycosides at m/z 204 and 217 indicated that 1
contained neutral sugars. MALDITOFMS (Figure S14,
Figure 8. 1H NMR spectrum of compound 1 in DMSO-d6, 700 MHz. See Figure S5 (Supporting Information) for expansions.
Figure 9. 13C NMR spectrum of compound 1 in DMSO-d6, 175 MHz. See Figure S6 (Supporting Information) for expansions.
Figure 10. Multiplicity-edited HSQC spectrum of compound 1 with
anomeric correlations indicated, DMSO-d6, 700/175 MHz. See
Figures S7 and S8 (Supporting Information) for expansions.
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Supporting Information) analysis showed an [M + Na]+ ion at
m/z 1218.117, consistent with an octasaccharide composed of
two arabinosyl, two xylosyl, and four glucosyl residues. GC-MS
analysis of the (S)-(+)-butyl glycoside TMS derivatives of 1 as
compared to standards (Figure S15, Supporting Information)
indicated D-glucose, D-xylose, and L-arabinose absolute
configurations, consistent with the natural abundances of
these monosaccharides.
The interglycosidic linkage positions were determined using
partially methylated alditol acetate derivatives of 1. These data,
evaluated in conjunction with the molar ratio and mass results,
indicated that 1 contained two terminally linked arabinofur-
anosyl residues, two 2-linked xylopyranosyl residues, one
terminally linked glucopyranosyl residue, one 4-linked
glucopyranosyl residue, and two 4,6-linked glucopyranosyl
residues.
Indicative partial fragmentation patterns from NSI-MSn
analyses of per-O-methylated derivatives of 1 were used to
Figure 11. Structure of compound 1 showing indicative 2D COSY and HMBC correlations with 13C and 1H chemical shifts indicated at each
position [δC (δH)]. Single-headed arrows indicate COSY correlations; double-headed arrows indicate HMBC correlations. For clarity, selected
correlations are shown on individual Ara-G/Ara-H and Xyl-E/Xyl-F glycosyl units. These resonances are duplicated for both Ara-Xyl side chains.
Figure 12. Portion of the semipreparative HPLC-ELSD chromato-
gram for HF2-2P1t22 (Polyamine), showing the resolution of isolated
components. Intensity of the A17 peak in this separation is greater
than that for other HF2-2P1t22 separations (Figure S39, Supporting
Information) due to co-injection of a portion of HF2-2P1t20.
Compounds eluting at A17, A18, and A19 were recovered in low
quantities and analyzed by analytical HPLC-ELSD on Atlantis dC18
(Figure S41, Supporting Information) and by 1H NMR spectroscopy
(Figure 13 and Figure S42, Supporting Information). Line overlay is
% composition of MeCN; counter solvent is water.
Figure 13. Comparison of the 1H NMR spectra for HF2-2P1t22A
fractions eluting at 17, 18, and 19 min, D2O, 400 MHz.
Chromatographic profile of these fractions is shown in Figure 12
and Figures S39 and S41 (Supporting Information). Arrows on the
A19 spectrum indicate characteristic arabinoxyloglucan anomeric
resonances. These spectra do not contain resonances in the regions
that are not displayed. The full spectrum and expansions for the HF2-
2P1t22A17 sample, of which 1 or a closely related compound may be
a primary component, are included in Figure S42 (Supporting
Information).
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confirm linkage positions and monomer connectivity. The
observation of key fragments produced from the partial
fragmentation of parent ions supported the presence of a
reducing glucosyl moiety connected via a single glycosidic
bond to the remainder of the molecule. It also permitted
placement of the two Xyl-Ara units on the two internal
glucosyl residues of the tetrameric glucosyl backbone. The
assignment of the side chains on the two internal glucosyl
residues is similar to that recently reported for the structure of
a cranberry arabinoxyloglucan heptasaccharide.44 Additional
detailed discussion of the MS fragmentation patterns in
support of structural assignments can be found in the
Supporting Information (Section S5 with associated Figures
S47−S61). All data obtained from the carbohydrate derivatiza-
tion analyses were used to assign the structure of 1 as shown,
with a D-glucopyranosyl-(1→4)-D-glucopyranosyl backbone
and two L-arabinofuranosyl-(1→2)-D-xylopyranosyl side chains
connected via D-xylopyranosyl-(1→6)-D-glucopyranosyl link-
ages.
NMR Spectroscopy. The use of NMR spectroscopy alone
was initially attempted for full, de novo, structural elucidation
of compound 1 employing spectra acquired at 400 MHz (data
not shown). As compound 1 was an unknown when structural
analysis began, DMSO-d6 was selected as the solvent, as it
provided better resolution across all proton resonances beyond
the anomeric region, and anomeric resonances could still be
identified using HSQC data (Figure 10; Figures S7 and S8,
Supporting Information). In general, the preferred solvent for
known or suspected carbohydrate compounds is D2O, as it
provides resolution of anomeric proton resonances without
overlap from those of hydroxy protons and allows for
comparisons to existing xyloglucan reference spectra.51 The
utility of D2O as an NMR solvent and the appropriate
application of associated reference spectra, however, depends
upon the availability of additional knowledge regarding
compound structure from non-NMR sources such as
derivatization techniques and MS. These approaches were
ultimately required for full structural elucidation of 1, thereby
establishing the xyloglucan nature of the compound and other
structural features. Additional acquisitions of NMR spectra for
1 at 700 MHz were, however, also obtained in DMSO-d6 to
allow for direct comparisons with previously obtained and
interpreted data for both compound 1 and related fractions
(e.g., HF2-2P1t22 comparison, Figure 14). Once the
xyloglucan oligosaccharide nature of 1 and the related series
of compounds had been firmly established, future studies of
cranberry oligosaccharides by our group were pursued using
D2O as the NMR solvent of choice.
47,48,52 The final structure
established for 1 was compared to those of purified cranberry
oligosaccharides,47,48 and the observation of strikingly similar
structures, in spite of the use of different structural elucidation
approaches, supported our preliminary hypotheses regarding
the probable presence of cranberry oligosaccharides in urinary
materials. 1H NMR spectra for the HF2-2P1t22A series (A17,
A18, and A19) in D2O (Figure 13; Figure S42, Supporting
Information) further supported the conclusion that the
oligosaccharide components present were xyloglucans and
Figure 14. Comparison of the HMQC spectra for HF2-2P1t20 and HF2-2P1t22 showing the similarity of composition for these fractions, DMSO-
d6, 400 MHz. Duplicated resonance sets indicated are for Xyl (δH/C 4.79/99.1) and Ara (δH/C 4.93/109.9) glycosyl residues. Oxymethylene,
glycosyl ring, and anomeric regions are indicated on the spectrum for HF2-2P1t22. 1H and 13C NMR spectra for these fractions are included in
Figures S32 and S33 (Supporting Information).
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allowed for later comparisons to cranberry fraction spectra
acquired in D2O.
47,52
NMR spectra (at 700 MHz in DMSO-d6) indicated the
presence of minor impurities, but, in conjunction with the
HSQC spectrum, permitted assignment of 1H and 13C NMR
data for compound 1 (Table 3, Figures S5−S8, Supporting
Information), and further interpretations of 2D data (Figures
S9−13, Supporting Information) provided partial structures
that were consistent with the results from chemical
carbohydrate analyses (Figure 11). NMR data were also used
to determine anomeric configuration and to support the
linkage positions and monomer connectivity indicated by the
mass fragmentation pattern data.
The use of DMSO-d6 as the NMR solvent reduced the
exchange of hydroxy protons with deuterium, limited hydrogen
bonding, and restricted the overall conformational flexibility of
the molecule, thereby allowing for the detection of COSY and
HMBC correlations between hydroxy protons and glycosyl
ring protons and carbons, respectively. These correlations were
used to support structural assignments and interglycosyl
connectivity (Figure 11). In particular, the proton (δH 4.59)
for the 2-hydroxy group of Glc-A allowed definition of the
partial structure for this ring. The proton resonance at δH 5.41
was determined to be a duplicated signal and was assigned to
the 3- and 2-hydroxy groups of Glc-C and Glc-D, respectively,
and HMBC correlations to this resonance permitted assign-
ment of the partial structures of both rings. The proton
resonance at δH 5.29 was also a duplicated signal for the 2-
hydroxy groups of both Ara-G and Ara-H units, and HMBC
and COSY correlations to this resonance permitted con-
firmation of Ara-Xyl interconnectivity.
The anomeric carbons of Glc-B, Glc-C, and Glc-D were
assigned β-configurations based on their shielded (δH < 4.70)
chemical shifts and coupling constants of JH1,H2 > 5 Hz, while
Xyl-E and Xyl-F were assigned α-configurations due to their
deshielded (δH > 4.70) chemical shifts and coupling constants
of JH1,H2 < 5 Hz.
51 The anomeric centers of the Ara-G and Ara-
H residues were assigned α-configurations based on their
chemical shifts and JH1,H2 values of 1−2 Hz; however, signal
overlap prevented accurate J-value assignments.51,53 The
reducing glucosyl residue was assigned to Glc-A, and its
presence confirmed by duplicate resonance sets for the α- and
β-anomeric protons at δH 4.92 and 4.35, respectively. COSY,
TOCSY, and HMBC (Figure 11; Figures S9−S13, Supporting
Information) correlations were used to confirm the identities
and connectivity of the constituent monosaccharide units.
HMBC correlations between H-1 of Araf-G and -H (δH 4.93)
and C-2 of Xylp-E and -F (δC 78.9) and between H-2 of Xylp-E
and -F (δH 3.21) and C-1 of Araf-G and -H (δC 109.9) directly
supported the assignment of α-L-arabinofuranosyl-(1→2)-α-D-
xylopyranosyl side chains. These side chains were linked to C-6
of the two internal glucosyl residues Glcp-B and -C through
HMBC correlations between H-1 of Xylp-E and -F (δH 4.79)
and C-6 of the two glucosyl units at δC 67.1. The connectivity
of the two internal glucosyl residues, Glcp-B and -C, was
confirmed through HMBC correlations between H-1 of Glcp-
C (δH 4.27) and C-4 of Glcp-B (δC 81.0).




copyranose. The 1H NMR data for other urinary oligosac-
Table 3. 1H and 13C NMR Assignments for 1, DMSO-d6, 700/175 MHz
monomer position δC δH (mult;
a JHH) monomer position δC δH (mult
a; JHH)
Glcp-A 1 92.2 4.92 (3.9) Glcp-D 1 103.5 4.36 (8.0)
α-anomer 2b 72.0 3.59 2b 73.2 3.12
3b 72.3 3.24 3b 75.1 3.37
4 81.7 3.32 4 73.7 3.63
5 77.3 3.21 5 81.5 3.38
6 61.5 3.61, 3.71 6 61.0 3.55, 3.75
Glcp-A 1 96.9 4.35 (6.8) Xylp-E 1 99.1 4.79 (3.3c)
β-anomer 2b 73.7 3.01 2 78.9 3.21b
3b 70.9 3.29 3 71.9 3.76
4 81.6 3.28 4 70.9 3.29
5 76.9 3.16 5 62.0 3.42
6 61.1 3.44, 3.72 Xylp-F 1 99.1 4.79 (3.3c)
Glcp-B 1 102.9 4.43 (8.1) 2 78.9 3.21
2b 73.1 3.15 3 71.9 3.76
3b 74.7 3.01 4 70.9 3.29
4 81.0 3.36 5 62.0 3.42
5 79.0 3.20b Araf-G 1 109.9 4.93d
6 67.1 3.70, 3.83 2 82.1 3.91
Glcp-C 1 103.8 4.27 (7.8) 3 77.6 3.63
2b 73.5 3.66 4 83.9 3.81
3b 75.2 3.40 5 61.7 3.42, 3.59
4 82.1 3.91 Araf-H 1 109.9 4.93d
5 79.0 3.20b 2 82.1 3.91
6 67.1 3.75, 3.83 3 77.6 3.63
4 83.9 3.81
5 61.7 3.42, 3.59
aAll protons appeared as overlapping multiplets unless otherwise indicated. bNumerical assignments are tentative due to signal overlap.
cApproximate J value. dA reliable numerical J value assignment could not be made due to signal overlap.
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charides isolated in low quantities (Figures 13 and 14; Figure
S42, Supporting Information) indicate that the composition of
1 is representative of the complex oligosaccharide pool. Spectra
collected in D2O at 400 MHz (Figure 13; Figure S42,
Supporting Information) contain anomeric resonances with
deshielded (δH > 5) chemical shifts, as are characteristic for
arabinoxyloglucans.47,48
Composition of Cranberry Materials. Cranberry sam-
ples CJ and CJA contained similar analytical-scale HPLC-UV/
ELSD profiles in the region of interest as active urine fraction
HF1-1 and analogous HF2-2, with the presence of a series of
UV-transparent components eluting between 16 and 25 min
with the optimized HPLC method (Figures 15 and 16; Figure
S16, Supporting Information). The cranberry material was
injected at 2−4 times higher concentrations than the urine
fractions, but retention times and relative peak ratios remained
similar and cranberry profiles could be directly overlaid with
those of the urine fractions from 16 to 25 min (Figure 15)
without postcollection processing of chromatographic data. As
ELSD is a semiquantitative, mass-sensitive method, these
observations indicate that a subset of similar components
appear to be present in both urine and cranberry materials at
similar concentration ratios. The overlay also shows that not all
components present in cranberry materials were detected in
the urine fractions of interest.
Direct, preparative, reversed-phase HPLC separation of
∼350 mg of CJ, using the methods applied to urine samples,
led to the collection of 22.2 mg of total material from the
region of interest (21.5−30 min, Figure 16). This material
represented ∼16% (w/w) of the total recovered CJ material
(139.8 mg) as being composed of oligosaccharides. This value
represents a minimum amount, as only 40% of the prepared
material was recovered, probably due to mass losses from
filtration and other handling steps, possible chromatographic
retention, and destructive ELS detection. Most CJ-P1 fractions
contained mixtures of compounds, but fraction CJ-P1t23 (4.0
mg) had similar HPLC-UV/ELSD characteristics to com-
pound 1 isolated from urine samples. Comparison of this
sample to that of the enriched fraction HF2-2P1t20, containing
primarily 1, via 1H NMR spectroscopy in DMSO-d6, confirmed
the similar chemical composition of the two materials (Figure
17). Insufficient pure material of CJ-P1t23 was available for full
structural characterization or bioassay testing, but 1H NMR
resonances in the anomeric region in DMSO-d6 indicated the
presence of an arabinoxyloglucan with eight monomeric units.
Fractions CJ-P1t22 and CJ-P1t25 also contained resonances in
the anomeric region indicative of arabinoxyloglucans (Figure
S17, Supporting Information). In contrast, a corollary fraction
to CJ-P1t38 was not detected in urine fractions, and this
material had a distinct 1H NMR profile from that of the urinary
oligosaccharides, but it is also likely an oligosaccharide. These
data indicate that the cranberry starting material contains a
series of oligosaccharides with structural compositions similar
to each other and to the isolated urinary oligosaccharides
(Figure 6), but that additional oligosaccharides and related
compounds may be present in cranberry materials that are not
excreted into urine.
Figure 15. Analytical HPLC-ELSD plots of CJA compared to HF1-1
and HF2-2 (raw data overlay). This comparative profile indicates that
urine and cranberry fractions have similar relative quantities of what
appear to be similar components (arrows). Samples were injected at
different concentrations as follows: CJA, 40 μL injection, 30 mg/mL;
HF1-1, 20 μL injection, 26 mg/mL; HF2-2, 25 μL injection, 10 mg/
mL. No retention time adjustments or other postacquisition
processing methods were applied to this data.
Figure 16. Preparative HPLC-UV/ELSD chromatograms for the CJ-
P1 separation (Atlantis dC18, R3). Comparison of these chromato-
grams indicates the presence of weak chromophores for a subset of
the compounds eluting from 0 to 8 min and the absence of
chromophores for the compounds eluting from 18 to 38 min. The
fraction t28 is not shown on this figure, as it is a mixture of
components eluting from 26 to 30 min. The absorbance profile from
38 to 46 min does not appear to correlate to the ELS profile of the
fraction eluting at 38 to 39 min, suggesting that fraction CJ-P1t38
lacks a chromophore. The components eluting from 38 to 46 min
showed a visible pink color in solution, suggesting the presence of
known anthocyanins, but the low mV intensity of this region indicates
relatively low concentrations of material. Line overlay is %
composition of water; counter solvent is MeOH.
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Separation of the CJA material using Sephadex LH-20 via
methods similar to those applied to urine samples yielded
oligosaccharide-containing fractions (e.g., CJA1-02) that,
combined, comprised ∼25% (w/w) of the starting material
and eluted at similar retention times as active urine fractions.
1H NMR spectroscopy in D2O indicated that these fractions
were enriched for arabinoxyloglucans similar in composition to
those found in active urine and in CJ-P1 fractions, as indicated
by characteristic profiles of anomeric resonances (Figure 18).
A full description of the isolation and structure elucidation of
two cranberry oligosaccharides from CJA Sephadex LH-20
column fractions and an additional source material is discussed
in the accompanying article;47 both compounds were found to
have structures similar to that of 1. Samples of CJ, CJA, and
selected CJA1 and CJA2 Sephadex LH-20 column fractions
were submitted to the bioassay used for testing urine fractions,
and samples that contained oligosaccharides were found to
have antiadhesion activity (Table 2).
Together, these data support the hypotheses that the UV-
transparent oligosaccharides present in active urine fractions
are directly derived from oligosaccharides present in the source
cranberry material and that the oligosaccharides present in
both urine and cranberry materials possess antiadhesion
properties.
Oligosaccharide Biochemical Origins and Mamma-
lian Digestion. The structure of 1 is closely related to those
of two arabinoxyloglucans isolated from the same cranberry
materials as used in this study (see accompanying article).47 It
is also similar to that of a cranberry arabinoxyloglucan
heptasaccharide, isolated after pectinase treatment of cranberry
as a part of commercial juice preparation processes.43,44 The
oligosaccharide series of interest has been detected in
cranberry juice concentrate and in commercially obtained
juice products, indicating that this group of compounds is
present in products available to consumers.52,54 Compound 1
and the reported cranberry arabinoxyloglucans are similar to
fragments derived from polymeric xyloglucans identified in
solanaceous plants.55 Such compounds are hemicellulose
polymers that serve as structural components of plant primary
cell walls. These polymers are enzymatically cleaved and
solubilized during the natural process of fruit ripening,55−57
but may also be released from cell wall components into fruit
products as a result of commercial fruit processing
procedures.58 Further research will be needed to investigate
the biochemical origins and structural complexity of the
cranberry oligosaccharide profile and the occurrence of these
and similar compounds in various food products.
Direct absorption and rapid elimination of unmodified
dietary oligosaccharides into mammalian urine would be
consistent with the reported rapid appearance of antiadhesion
activity in human urine after the consumption of cranberry
juice.33 Oligosaccharides with various structures have been
previously isolated from normal human urine,59 and reports
have shown that mixtures of complex oligosaccharides ranging
in size from trimers to heptamers and larger can be ingested
and subsequently found in adult and infant human urine.60,61
Mice gavaged with high doses of globotriose [Gal-(α1→4)-
Gal-(β1→4)-Glc] were found to rapidly clear this trisaccharide
from plasma (t1/2 = 6 min) and excrete it primarily into urine
without metabolic biotransformation at levels of >5 mg/mL for
4−12 h after administration, indicating that this compound is
orally bioavailable and retained for later excretion over time.62
Preliminary data from the present study indicate that a
minimum of 0.13−0.25% of ingested cranberry oligosacchar-
Figure 17. Comparison of the 1H NMR spectra for the urinary fraction HF2-2P1t20, enriched for compound 1, and an enriched cranberry
oligosaccharide fraction CJ-P1t23 (4 mg), DMSO-d6, 400 MHz. Spectra for both fractions were highly similar, indicating similar chemical
composition. These data indicated that the cranberry material CJ-P1t23 was also an arabinoxyloglucan oligosaccharide.
Figure 18. 1H NMR spectra for active fractions CJA1-02 and CJA2-
03, D2O, 400 MHz. These spectra show the similarity of composition
for oligosaccharide-enriched fractions from Sephadex LH-20 columns
CJA1 and CJA2.47 These spectra do not contain resonances in the
regions that are not displayed.
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ides were excreted into urine, supporting the hypothesis that
orally ingested cranberry oligosaccharides may also be excreted
through feces or retained in body compartments and excreted
into urine over time. As the swine used in this study were fed
relatively high doses of cranberry material to ensure detection
and isolation of possible antiadhesive components, further
studies will be necessary to determine in vivo mammalian
urinary excretion levels of oligosaccharides after the con-
sumption of more typical quantities of cranberry materials.
Hemicellulose polymers and oligomers such as arabinox-
yloglucans are generally considered to be a type of dietary
fiber, as they are water-soluble, acid stable, and resistant to
degradation during the early stages of mammalian digestion, as
mammals lack β-glucosidase digestive enzymes.63,64 While
mammalian enzymes may not be able to metabolize the
cellulosic β-(1→4)-linked glucose backbones of 1 and the
cranberry oligosaccharides,47,48 fecal microbes, such as specific
Bif idobacterium longum subspecies, have been identified that
are able to ferment cranberry xyloglucans.65 It is therefore
possible that oligosaccharides from plant sources may be
excreted via both urinary and fecal routes, both with and
without biotransformation. Furthermore, the fermentation of
cranberry oligosaccharides by fecal microbes may have
beneficial effects on gut composition and function such as
those that have been observed for other dietary oligosacchar-
ides.66 Effects of cranberry oligosaccharides on the gut
microbiome may therefore contribute to the reported systemic
anti-inflammatory properties and other gut-associated health
benefits attributed to cranberry products.67 While this study
did not directly investigate the fecal excretion of cranberry
oligosaccharides, the observation that less than 1% of the
ingested oligosaccharides were probably excreted via the
urinary pathway suggests that the remaining material was
eliminated by the fecal route, and further work will be needed
to fully characterize the absorption, metabolism, and excretion
of cranberry oligosaccharides in mammalian systems.
Oligosaccharide Antiadhesion Properties. Oligosac-
charides in general are recognized to be natural interference
ligands and are of significant medical interest for the
prevention of infections.58,68−72 Carbohydrates are well
recognized as bioactive components that can prevent P-
fimbriated E. coli adhesion, and globotriose [α-D-Gal(1→4)β-
D-Gal(1→4)β-D-Gal] is able to inhibit adhesion both in vitro
and in vivo by binding to P-fimbriae in place of cell surface
receptors.62 Previous studies have shown that mixtures of
neutral oligosaccharides isolated from breast milk and the urine
of breast-feeding babies are also able to interfere with E. coli
adhesion.60,61 Complex carbohydrates and oligosaccharide
mixtures possess superior antiadhesion abilities as compared
to mono- or disaccharides and may have increased efficacy at
preventing adhesion due to their ability to mimic host cell
carbohydrate receptors via simultaneous interactions with
multiple bacterial adhesions.70−72 Human milk oligosacchar-
ides have been shown to have direct protective effects on
human bladder epithelial cells in response to challenge by
uropathogenic E. coli,73 and such a mechanism may also
contribute to the role cranberry compounds play in the
prevention of UTIs. A cranberry oligosaccharide fraction has
been shown to inhibit biofilm formation by E. coli in vitro,45
and the bioassay results in this and our other studies47,52
provide additional evidence that cranberry oligosaccharide
mixtures can inhibit E. coli adhesion. Mixtures of cranberry
oligosaccharides, rather than single compounds, may act as
natural inhibitors of bacterial adhesion and may have additive
or synergistic effects with other compounds from cranberry,
but further investigations will be needed to elucidate the
mechanisms involved.
Multiple compounds are likely to contribute to the overall
antiadhesion properties of cranberry materials,37−39,74 and
additional studies will be required to fully elucidate the
possible roles of oligosaccharides in the various biological
properties attributed to cranberry. Further isolation and
structural elucidation studies will be necessary to fully
characterize the complex series of oligosaccharides present in
various cranberry materials and in urine or feces after cranberry
consumption. Future efforts will also need to focus on the
development of analytical methods for the detection and
quantification of this class of compounds in various cranberry
products and in biofluids after the consumption of cranberry
products. While other, possibly non-oligosaccharide, com-
pounds were detected in some of the crude fractions with
antiadhesion activity, attempts to isolate these compounds for
further analysis were unsuccessful. The consistent presence of
oligosaccharides in antiadhesive fractions combined with the
results from three different bioassays that show antiadhesive
properties for cranberry oligosaccharides mixtures47,52 further
supports the hypothesis that oligosaccharides are, in some way,
involved in the antiadhesive properties of cranberry materials.
In conclusion, this study shows that a group of compounds
found in antiadhesive swine urine fractions are oligosaccharides
that are similar in structure to those found in analogous
antiadhesive cranberry fractions. Cranberry-derived oligosac-
charides are therefore potentially significant constituents that
contribute to the antiadhesion effects of urine produced as a
result of cranberry product consumption. This hypothesis
provides a new guiding paradigm for future research regarding
the antiadhesive constituents of cranberry.
■ EXPERIMENTAL SECTION
General Experimental Procedures. Regular solvents, HPLC
solvents, and most reagents and general lab materials were obtained
from Fisher Scientific, Inc. (Waltham, MA, USA), Sephadex LH-20
and additional materials (including apple pectin) were obtained from
Sigma-Aldrich, Inc. (St. Louis, MO, USA), HPLC sample filters were
obtained from Millipore, Inc. (Billerica, MA, USA), and NMR
solvents were obtained from Cambridge Isotope Laboratories, Inc.
(Andover, MA, USA).
Source Materials. Spray-dried cranberry hull extract powder
(Vaccinium macrocarpon Ait., Ericaceae) (a.k.a. cranberry powder, CJ)
was supplied by Ocean Spray Cranberries, Inc. (Lakeville-Middleboro,
MA, USA) and was used for direct separations and analytical studies
and for the feeding of swine. This powdered material was created by
spray-drying cranberry juice (cranberry hull extract) that had been
produced via proprietary methods. The CJ powder was fully soluble in
water and produced a dark burgundy solution that was similar in
appearance (see accompanying article47 for images) to commercially
available cranberry juice products prepared from cranberry juice
concentrate. Further studies by our research group have shown that
the CJ material contains a similar oligosaccharide profile as that of
commercially obtained cranberry fruit powder47 and cranberry juice
concentrate (provided to us by Ocean Spray Cranberries, Inc.).52 Our
studies have also found that commercially available cranberry juices
contain detectable levels of a similar oligosaccharide series.54
Five separate feedings were performed in this study to produce
sufficient amounts of cranberry-derived urine with antiadhesion
activity;42 materials from three of these feedings (designated F, H,
and I; Table 1) are discussed in this publication and the Supporting
Information. Animal protocols were approved by the University of
Wisconsin Review Committee (approval number A3368-01, 04/25/
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2002). Adult female sows (ca. 160 kg each) were housed in gestation
crates at the Livestock Laboratory on the University of Wisconsin−
Madison campus and were offered a maintenance amount of a basal
diet consisting of corn and soybean supplemented with tryptophan,
methionine, lysine, and various vitamins and minerals as necessary to
meet the National Research Council recommended requirements for
maintenance.75 Sows were chosen due to their similar metabolism to
that of humans and because they can be fed a consistent diet
supplemented with relatively large quantities of cranberry powder per
day.76 Sows also generate the volumes of urine (∼1−2 L/d) necessary
to provide sufficient material for bioassay-guided fractionation and
metabolite purification.
Cranberry powder was mixed with basal diet components at an
administration rate of 800 g powder/day/sow (∼5 g/kg body weight)
for 3−5 days prior to collection of treatment urine. Feeding was
continued through the collection period of 3−4 days, and urine (2.0−
6.5 L per sow) was collected via Foley catheters. Control urine (∼2
L) was collected via catheter prior to initiating the feeding of
cranberry powder. Urine was collected in containers placed over ice,
containers were emptied at 4 h intervals, and urine was frozen at −20
°C immediately after collection. Animals were monitored twice daily
and Foley catheters checked regularly by research staff during
collection periods. Details of the urine collections that provided
material used in this report are shown in Table 1. Aliquots (∼5 mL
each) of each urine collection were frozen and sent to Rutgers
University for preliminary bioassay testing (results not shown), and
remaining urine was shipped to the University of Mississippi as frozen
liquid on dry ice.
Anti-Hemagglutination Assay. Anti-hemagglutination assays
are commonly used to assess bacterial adherence to eukaryotic cells,
as the agglutination of (A1, Rh+) human red blood cells by P-
fimbriated E. coli is due in part to the binding of the E. coli PapG
adhesin to the α-Gal(1→4)β-Gal disaccharide binding epitope found
on the surface of these cells.77,78 The assay used for this study was
performed as described previously with minor modifications.24,25 This
in vitro assay has been used to identify PACs as antiadhesive
constituents of cranberry samples24 and to detect antiadhesion
properties of raw human urine samples.33
Bacterial Strains. Clinical strains of uropathogenic P-fimbriated E.
coli (UPEC) were isolated and cultured as described previously,24
with the modification that P-fimbriated bacteria were not washed to
prevent fimbriae from breaking off, and were suspended directly in
phosphate-buffered saline (PBS, pH 7.0) at a concentration of 5 × 108
bacteria/mL PBS for testing. Cultures were kept on agar slants at 4 °C
for short-term use over several months, and strains were kept frozen at
−70 °C in tryptose broth (30% glycerol) for long-term storage.
Hemagglutination Assessment and Relative Activity. Test
samples were dissolved in different volumes of PBS based on the
amount of sample provided (e.g., 150 μL for 10−30 mg, 200 μL for
40−70 mg, 400 μL for >80 mg) and adjusted to neutral, physiologic
pH (between 5.5 and 7.0) with 1 N NaOH. Serial 2-fold dilutions of
each test sample were prepared in PBS and were tested as described
previously.24,25 Hemagglutination was visually assessed using a scoring
system to determine dilution end points (Section S1a, Supporting
Information).
Dilution end point results were compared and interpreted using a
qualitative scale (Section S1b, Supporting Information), modified
from one used previously with this assay,24 to determine the relative
activity of a sample and whether it could possibly prevent UPEC−
epithelial cell adhesion. Use of this scale allowed for comparisons
across sample types and across submitted sets over time. This scale
was based on four criteria: (1) the numerical dilution end point, (2)
the number of 2-fold dilutions applied to the sample, (3) the activity
of the sample relative to a parent fraction, and (4) a comparison of
results from replicate samples, if available (Table S7, Supporting
Information). Relative sample activity using this scale was assigned as
follows: “+ +” = active; “+” = probably active; “+/−” = may or may
not be active; “−” = probably not active; and “− −” = not active.
Bioassay Test Samples. Selected samples were coded, randomized,
and submitted as dry powders (∼10−400 mg per sample). Sample
sets were shipped by overnight post on cold packs or dry ice.
Duplicate or triplicate samples were submitted for parent materials
and some fractions, but sample quantity limitations and the labor-
intensive nature of the assay made it impractical to submit triplicate
samples for every sample tested in every sample set. To account for
assay variations over time, selected urine fractions were repeatedly
tested with each set of samples submitted. These included control
urine samples and fractions and the parent fractions for each
separation step.
Isolation Methods for Urine Samples. Frozen liquid urine was
thawed overnight at room temperature. A general purification
protocol (Figure 4) was applied to the four batches of urine (FC,
F, H, and I). Crude urine was centrifuged (5 min at 2500 rpm) or
gravity filtered (Whatman #1) to remove casts and solids. A portion
of each clarified urine batch was removed and lyophilized to serve as a
pre-extraction control sample. Clarified urine aliquots (1 L each) were
partitioned with EtOAc ((2−4) × 250 mL) or EtOAc/MeOH ((2−
4) × 50:250 mL MeOH/EtOAc). EtOAc and aqueous urine fractions
(FC1, FF, HF, IF) were evaporated under reduced pressure with a
water bath temperature of ∼40 °C. Dried EtOAc fractions were
dissolved in water, aqueous samples were diluted as necessary, and all
samples were frozen and lyophilized. Repeated dilution and
lyophilization was necessary for highly hygroscopic samples and
subsequent fractions. All samples were stored as dry powders or
concentrated syrups (hygroscopic samples) in airtight containers at
−20 °C. Control urine (FC) was partitioned using the procedures
developed for the active urine samples, but was processed only to the
stage of analytical-scale, reversed-phase HPLC (step 4, Figure
4; Section S2a, Supporting Information). Control urine fractions
were submitted to the bioassay as negative controls.
Dried aqueous urine fractions (FF, HF, IF; 10−50 g per column)
were chromatographed on Sephadex LH-20 (various column
dimensions) using 50% or 70% EtOH for FF separations and 70%
EtOH for HF and IF separations (isocratic) (Tables S2−S4,
Supporting Information). Eluent was collected in tubes (5 to 25
mL each), and tubes were combined based on appearance and relative
elution volume to give 5−8 total fractions per column. Fractions were
dried as described above. Selected Sephadex LH-20 fractions were
submitted for bioassay testing and further purified using HPLC-UV/
ELSD. The optimum method involved preparative reversed-phase
HPLC on Waters Atlantis dC18 sorbent followed by semipreparative,
normal-phase HPLC on YMC Polyamine II sorbent (Section S3,
Supporting Information).
Isolation Methods for Cranberry Samples. Cranberry powder
(CJ) was directly separated by preparative HPLC-UV/ELSD (Atlantis
dC18) using a similar method to that applied to urinary fraction HF2-2
(Figure 16). Two batches of CJ (99.2 and 250 mg) were dissolved in
water (0.80 and 1 mL, respectively), filtered (0.2 μm nylon filter), and
separated (200 and 500 μL injections at 124 mg/mL and 1 mL
injection at 250 mg/mL). Eluent was combined based on chromato-
graphic profile and retention time to give fractions CJ-P1t22 (21.5−
22.7 min, 3.3 mg), CJ-P1t23 (22.8−23.7 min, 4.0 mg), CJ-P1t25
(23.8−25.8 min, 7.3 mg), CJ-P1t28 (25.9−30.0 min, 7.6 mg), and CJ-
P1t38 (6.5 mg), as well as others. These fractions were analyzed by
1H NMR spectroscopy. Additional fractions collected did not yield
enriched or purified compounds but accounted for 117.6 mg of
additional material recovered from the two combined CJ-P1
separations.
Cranberry powder was also extracted and separated using the
general protocol applied to urine samples (Figure 4). Aliquots of CJ
(1.24 kg, in 80−120 g batches) were dissolved in water (450 mL/100
g) and extracted with EtOAc (10 × 1:3 v/v EtOAc/water). The
EtOAc extracts (CJE) were combined (12.706 g; 1.02% w/w of CJ)
and dried, and the residual amorphous burgundy solid was
resuspended in a minimum amount of water and lyophilized. Aqueous
material (CJA) was combined, evaporated under reduced pressure to
remove residual organic solvent, diluted with water if necessary,
frozen, and lyophilized in 1−2 L batches.
Fraction CJA was compared to urine fractions HF1-1 and HF2-2
by analytical HPLC-UV/ELSD (Figure 15) using the same method as
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applied to urine fractions (Atlantis dC18, 4.6 × 150 mm, 5 μm).
Samples of CJA (40 μL injection, 30.0 mg/mL), HF1-1 (25 μL
injection, 10.0 mg/mL), and HF2-2 (20 μL injection, 26.0 mg/mL)
were prepared in a single session and were sequentially separated
using identical methods without flow interruptions between
injections. The column was washed and re-equilibrated with a
minimum of 10 column volumes of the starting solvent before each
injection.
An aliquot of CJA (25.6 g) was fractionated on Sephadex LH-20
using protocols similar to those developed for urine samples. The CJA
sample was dissolved in water, and EtOH (100%) was added
gradually with intermittent sonication to give a final concentration of
70% EtOH (100 mL). The sample was briefly centrifuged to remove
precipitate and was chromatographed on Sephadex LH-20 (7 × 37
cm) with 70% EtOH (isocratic) at 1.5−1.7 mL/min. Eluent was
collected in 20−25 mL aliquots that were combined based on
appearance and elution volume and dried as above to give 12 fractions
including CJA1-02 (3.649 g), CJA1-03 (1.280 g), CJA1-04 (1.669 g),
and others. Selected materials were submitted for bioassay testing and
further characterized by 1H NMR spectroscopy and HPLC-UV/
ELSD. A second aliquot of CJA (CJA2) was later separated on
Sephadex LH-20 and further purified by HPLC as discussed in the
accompanying article.47
HPLC Separation Procedures. Reversed-phase samples were
dissolved in a minimum amount of water, while normal-phase samples
were dissolved in a minimum amount of either water or, at most, 60%
MeOH. All samples were syringe-filtered with 0.2 μm filters (nylon or
PTFE, 13 or 33 mm), and various amounts of material were injected
per separation depending on the nature of the sample, the column,
and the chromatographic conditions used (Section S3, Supporting
Information). No postacquisition processing, retention time adjust-
ments, or other modifications were made to the HPLC data shown in
this report or associated materials.
Analytical-scale HPLC separations were performed on a Waters
2695 separations module equipped with a Waters 996 photodiode
array (PDA) detector connected in series to a Polymer Laboratories
PL-ELS2100 detector (ELSD). “Max plot” chromatograms (210−400
nm) were extracted from PDA data for detection of UV-active
metabolites. Columns used included a Waters Atlantis dC18 (4.6 ×
150 mm, 5 μm particle size) equipped with a guard column of the
same sorbent (4.6 × 20 mm) and a YMC Polyamine II (Polyamine)
(10 × 150 mm, 5 μm particle size, 12 nm pore size). The Atlantis
dC18 column was used with a flow rate of 1 mL/min as follows: 5 min
100% water, 30 min gradient from 100% water to 30% MeOH, 20 min
gradient from 30% to 100% MeOH, and 5 min 100% MeOH. The
Polyamine column was used with a flow rate of 2.5 mL/min as
follows: 5 min 100% MeCN, 20 min gradient from 100% to 60%
MeCN, 10 min 60% MeCN, and 10 min gradient from 65% to 40%
MeCN, with a counter solvent of water. Each column was allowed to
equilibrate in the starting solvent conditions for a minimum of 10
column volumes prior to each sample injection.
Preparative-scale HPLC separations were performed using a Waters
Delta Prep 4000 chromatographic system equipped with an LC
controller and a 2487 dual-wavelength UV detector connected in
series to a Polymer Laboratories PL-ELS1000 ELSD. Fractions were
collected in parallel with ELS monitoring through the use of a flow
splitter installed in the output line after the UV flow cell. A
preparative Waters Atlantis dC18 column (19 × 250 mm, 10 μm
particle size) was used with a flow rate of 25 mL/min as follows: 5
min 100% water, 30 min gradient from 100% water to 20% MeOH, 10
min gradient from 20% to 100% MeOH, and 3 min 100% MeOH. A
semipreparative YMC Polyamine II column (10 × 150 mm, 5 μm
particle size, 12 nm pore size) was used with a flow rate of 4 mL/min
as follows: 5 min 65% MeCN and 25 min gradient from 65% to 45%
MeCN, with a counter solvent of water. Guard columns were not
used. Fractions were combined based on retention time and
chromatographic profile and dried as above. Each column was
allowed to equilibrate in the starting solvent conditions for a
minimum of 10 column volumes prior to each sample injection.
ELSD settings varied based on the solvent systems used and the
inlet solvent flow rate. Settings remained constant throughout each
separation. The ELSD was allowed to equilibrate for at least 30 min at
the specified settings prior to initial data acquisition for a given
session and additionally for 10−20 min at the starting conditions for
each separation. All eluent from analytical separations was directed
through the ELSD. The HPLC instrument was configured for split
detection−collection for semipreparative and preparative separations:
for Polyamine separations, ∼0.5−1 mL/min of eluent was delivered to
the ELSD with the remaining ∼2−2.5 mL/min delivered to a
collection vessel, while for Atlantis dC18 separations, ∼1−3 mL/min
of eluent was delivered to the ELSD with ∼22−24 mL/min delivered
to a collection vessel. Typical ELSD settings for Atlantis dC18
separations were a gas flow rate of 0.8−1.2 SLM, an evaporator
temperature of 100 °C, and a nebulizer temperature of 50 °C, while
those for the Polyamine column were a gas flow rate of 1.0−1.2 SLM,
an evaporator temperature of 90 °C, and a nebulizer temperature of
45 °C.
Structure Elucidation. NMR Spectroscopy. Bruker Avance III
400 MHz spectrometers equipped with either Ultrashield or
Ultrashield Plus magnets and 3 mm probes were used to obtain 1H
and 2D NMR spectra for crude and enriched fractions. A Bruker
Avance 700 MHz spectrometer with a 5 mm CPTCI cryoprobe was
used to obtain the 1D and 2D NMR data used for assigning the
structure of compound 1. Samples for NMR analysis were prepared
by dissolving 2−10 mg of material in a minimal amount of high-purity
DMSO-d6 (99.99%) or D2O (99.99%).
Carbohydrate Structural Analyses. Compound 1 was found to be
a complex carbohydrate and was submitted to the Complex
Carbohydrate Research Center (CCRC) at the University of Georgia
(Athens, GA, USA). Analyses necessary for full structural elucidation
required derivatization of the sample and provided information on
glycosyl composition, glycosyl linkage positions, high-resolution mass
by MALDIMS, oligosaccharide sequence, and monomer config-
uration. Details of the standard methodologies employed are included




syl-(1→4)-β-D-glucopyranose (1): white, amorphous powder; 1H and
13C NMR data, Figures 8 and 9, Figures S5 and S6 (Supporting
Information), and Table 3; 2D NMR data, Figures 10 and 11 and
Figures S7−S13 (Supporting Information); MALDIMS (positive ion
mode) [M + Na]+ at m/z 1218.117, to give a calculated molecular
formula of [C44H74O37+Na]
+ (Figure S14, Supporting Information).
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